California Retina Consultants
13
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
31%
4 trials in Phase 3/4
60%
6 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
Role: collaborator
Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study)
Role: lead
Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema
Role: lead
Variable Interval Versus Set Interval Aflibercept for DME
Role: lead
Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
Role: lead
Analysis of Aqueous and Vitreous Humor
Role: lead
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Role: lead
Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab
Role: lead
Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
Role: lead
Eye Drop Application Monitor, Pilot Study
Role: collaborator
Assessment of Comfort Level Following an Intravitreal Injection by 30 or 32 Gauge Needles
Role: collaborator
Lucentis for Central Retinal Vein Occlusion (CRVO)
Role: lead
Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion
Role: lead
All 13 trials loaded